Novo Nordisk: CagriSema Disappoints Again

Core Viewpoint - Shares of Novo Nordisk A/S (NVO) have declined following disappointing phase 3 results for CagriSema, which was unexpected given the anticipated consensus shift in treatment approaches [2] Group 1: Company Performance - Novo Nordisk A/S reported underwhelming phase 3 results for its drug CagriSema, leading to a drop in its stock price [2] Group 2: Market Reaction - The market's reaction to the phase 3 results was surprising, indicating a potential disconnect between investor expectations and the actual outcomes [2]